Answer
Atezolizumab (Tecentriq), in combination with bevacizumab, is indicated for adults with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy.
Sources for this answer
- Tecentriq 840 mg and 1,200 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.1 Therapeutic Indications · Version 41Document updated
Sources checked